# Acute Myeloid Leukemia, Not Having Achieved Remission (C92.00)OverviewAcute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation and accumulation of abnormal, immature myeloid cells (blasts). When a patient is diagnosed with "Acute myeloid leukemia, not having achieved remission" (ICD-10 C92.00), it indicates that despite initial therapeutic interventions, the disease persists, and a state of complete remission has not been attained. This status signifies either primary refractory disease, where the leukemia fails to respond adequately to induction chemotherapy, or very early relapse, where a transient, incomplete response quickly reverts to active disease. Patients in this state face significant challenges and require intensive, often salvage-oriented, treatment strategies.## PathophysiologyAML originates from malignant transformation of hematopoietic stem cells or progenitor cells in the bone marrow, specifically those committed to the myeloid lineage. This transformation leads to a block in cellular differentiation, causing an accumulation of immature myeloid blasts. These blasts proliferate uncontrollably, crowding out normal hematopoietic cells in the bone marrow, leading to bone marrow failure. This failure manifests as cytopenias: anemia (lack of red blood cells), thrombocytopenia (lack of platelets), and neutropenia (lack of mature neutrophils, a type of white blood cell).The pathophysiology of AML is heterogeneous and is driven by a complex interplay of genetic and epigenetic alterations. Common genetic mutations include those in FLT3 (FMS-like tyrosine kinase 3), NPM1 (nucleophosmin 1), CEBPA (CCAAT/enhancer-binding protein alpha), IDH1/IDH2 (isocitrate dehydrogenase 1 and 2), and RUNX1. Chromosomal translocations, such as t(8;21), inv(16), and t(15;17) (characteristic of Acute Promyelocytic Leukemia, a subtype of AML), also play critical roles in oncogenesis and disease progression.The persistence of leukemic stem cells (LSCs) is a key factor in refractory disease. These LSCs possess self-renewal capabilities and are often resistant to conventional chemotherapy, enabling the leukemia to evade eradication and preventing the achievement of remission. Failure to achieve remission often implies a more aggressive disease biology, complex genetic aberrations, or the development of chemotherapy resistance mechanisms within the leukemic clone.## Clinical PresentationPatients with AML not having achieved remission will often present with persistent or recurrent symptoms related to bone marrow failure and organ infiltration. Symptoms of anemia may include profound fatigue, pallor, dyspnea on exertion, and weakness. Thrombocytopenia leads to increased bruising, petechiae, purpura, epistaxis (nosebleeds), gingival bleeding, and menorrhagia (heavy menstrual bleeding). Neutropenia predisposes patients to recurrent or severe infections, often manifesting as persistent fever, sepsis, or localized infections that are difficult to treat.Extramedullary involvement, while less common, can also contribute to symptoms, including hepatosplenomegaly (enlarged liver and spleen), lymphadenopathy (enlarged lymph nodes), gingival hypertrophy (swollen gums, particularly in monocytic AML subtypes), leukemic cutis (skin infiltrates), and, rarely, central nervous system (CNS) involvement leading to headaches, cranial nerve palsies, or other neurological deficits. For patients in the C92.00 status, these symptoms may have been present initially and persisted despite induction therapy, or they may have briefly improved before worsening again. Laboratory findings will typically show circulating blasts in the peripheral blood and/or a high percentage of blasts (>5%) in the bone marrow after a course of induction therapy.## Diagnostic Criteria and Definition of "Not Having Achieved Remission"The initial diagnosis of AML generally requires at least 20% blasts in the bone marrow or peripheral blood, or the presence of specific recurrent genetic abnormalities (e.g., t(8;21), inv(16), t(15;17)) irrespective of blast percentage. Diagnosis involves a comprehensive evaluation including complete blood count with differential, peripheral blood smear review, bone marrow aspiration and biopsy, immunophenotyping (flow cytometry) to confirm myeloid lineage, cytogenetic analysis, and molecular genetic testing (e.g., for FLT3-ITD, NPM1, IDH1/2 mutations).The status "not having achieved remission" is clinically defined when, after completing a standard course of induction chemotherapy, the criteria for complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) are not met.Complete remission (CR) is typically defined by:1. <5% blasts in the bone marrow.2. Absence of circulating blasts or blasts with Auer rods.3. Absence of extramedullary leukemia.4. Recovery of peripheral blood counts (absolute neutrophil count >1.0 x 10^9/L, platelet count >100 x 10^9/L).If a patient still has >5% blasts in the bone marrow, persistent blasts in the peripheral blood, or evidence of extramedullary disease after induction, they are considered to have primary refractory AML, and thus have not achieved remission. In some cases, molecular or cytogenetic remission is also monitored; persistent abnormalities, even with morphological remission, may indicate a higher risk of relapse and could influence subsequent treatment decisions.## Standard of CareThe management of AML not having achieved remission is complex and highly individualized, focusing on achieving a subsequent remission, ideally as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT), which remains the only potentially curative therapy for many patients.Treatment strategies include:1. **Salvage Chemotherapy Regimens:** These are typically more intensive than initial induction therapies or involve different drug combinations. Common regimens include high-dose cytarabine (HiDAC) based therapies, such as FLAG-IDA (fludarabine, cytarabine, G-CSF, and idarubicin) or MEC (mitoxantrone, etoposide, and cytarabine). These aim to reduce the blast burden sufficiently to achieve a second remission.2. **Targeted Therapies:** The availability of targeted agents has revolutionized treatment for specific AML subtypes: * **FLT3 Inhibitors:** For patients with FLT3 mutations (e.g., FLT3-ITD, FLT3-TKD), drugs like gilteritinib, midostaurin, or quizartinib can be highly effective, either as monotherapy or in combination with chemotherapy. * **IDH1/IDH2 Inhibitors:** For patients with IDH1 or IDH2 mutations, ivosidenib (IDH1) and enasidenib (IDH2) offer targeted options. * **Venetoclax Combinations:** Venetoclax, a BCL-2 inhibitor, often combined with hypomethylating agents (e.g., azacitidine, decitabine) or low-dose cytarabine, has shown significant efficacy, particularly in older or unfit patients, and is increasingly used in refractory settings.3. **Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT):** This is considered the best post-remission strategy for eligible patients, especially those with intermediate or high-risk disease, once a second complete remission (or even a partial response) has been achieved with salvage therapy. Conditioning regimens are used to ablate residual leukemic cells before infusion of donor stem cells.4. **Clinical Trials:** Enrollment in clinical trials for novel agents, immunotherapies (e.g., CAR T-cells, bispecific antibodies), or experimental combinations is often considered for patients with refractory AML, offering access to cutting-edge treatments when standard options are limited.5. **Supportive Care:** Throughout treatment, comprehensive supportive care is crucial, including blood product transfusions, aggressive management of infections with broad-spectrum antibiotics and antifungals, pain management, and nutritional support.6. **Palliative Care:** For patients who are not candidates for intensive treatment or for whom multiple lines of therapy have failed, a focus on palliative care to manage symptoms and optimize quality of life becomes paramount.